Multiple endocrine neoplasia type 1 (MEN-1) is inherited as an autosomal dominant disease characterised by hyperplasia or neoplasia of the parathyroids, anterior pituitary and the endocrine pancreas (Wermer, 1954) . Recently, both parathyroid and pancreatic lesions in MEN-1 have been reported to show allelic loss of heterozygosity on chromosome 11 (Larson et al., 1988; Friedman et al., 1989; Thakker et al., 1989; Yoshimoto et al., 1989) . In the case of the parathyroid, a similar change was reported with sporadic adenoma (Friedman et al., 1989) . We believe the present study is the first report of allelic loss in a sporadic pancreatic endocrine tumour. The genetic pattern of two pancreatic endocrine tumours (one a sporadic glucagonoma and the other a neuroendocrine pancreatic tumour from a patient with MEN-1) was studied using the INT-2 (SS6) probe which maps to chromosome 11 band q13 (Casey et al., 1986) .
The MEN-1 patient was a 23-year-old female with a strong family history of MEN-1 involving her father and his 4 siblings, and 4 of the patient's paternal cousins. From the age of 18 years, she complained of amenorrhea, increased appetite and weight gain. Serum calcium was elevated and abdominal ultrasound showed a mass 4 cm in diameter in the head of the pancreas. This pancreatic tumour was treated by local excision and histology of the tumour including immunohistochemical staining, indicated a neuroendocrine tumour of uncertain type. The second patient with a histologically confirmed pancreatic glucagonoma was considered to be a sporadic case as there was no family history of endocrine disease and the patient's serum calcium, prolactin and gastrin were all normal.
Peripheral blood from which high molecular weight DNA was extracted (Miller et al., 1988) was obtained from both patients as well as the affected parent (father). A portion of each tumour was sent for histological examination and the remainder used for DNA extraction following pulverisation in liquid nitrogen. DNA was digested with Taq 1 for the sporadic case and BamHl for the MEN-1 case and separated through 1.2% or 0.8% agarose gels respectively before transfer to nylon membranes (Southern, 1975) . The INT-2 (SS6) was radiolabelled by random priming (Rigby et al., 1977) using a32P-dCTP and hybridisation was carried out at 65°C (Freytag, 1988) . Figure 1 shows that the constitutional DNA from both both a sporadic and a familial (MEN-l) pancreatic tumour were associated with allelic loss at the same locus (Figure 1) . To the best of our knowledge this is the first report detailing an allelic loss in a sporadic pancreatic tumour and indicates the possibility that both sporadic and MEN-I associated pancreatic tumours share the same final genetic basis. Oncogenesis in the MEN-1 case resulted when the normal allele was lost thereby unmasking the mutated allele. Since the affected father was homozygous (1,1) and the affected daughter was heterozygous (1,2), allele 2 (i.e. the normal alrele) must have been inherited from the unaffected mother. The sporadic pancreatic tumour presumably involved a mutation and a deletion of the normal allele in a similar manner except that both these chromosomal alterations occurred in the somatic cells. These conclusions are consistent with Knudson's two-hit theory of carcinogenesis (Knudson et al., 1976) and are supported by the findings for sporadic and familial (MEN-l associated) parathyroid tumours which have also been shown to have allelic loss within chromosome band 11q13 (Friedman et al., 1989; Thakker et al., 1989) . It is possible in MEN-1, however, that the second lesion may not be at the putative disease locus, a situation analagous to that found in Wilm's tumour, where there is loss of heterozygosity which does not seem to be at the site of the gene which leads to inherited susceptibility. The loss of somatic heterozygosity observed in this study also suggests that both the sporadic and familial pancreatic tumours are monoclonal at the time of clinical presentation, since allelic loss must be present in most of the tumour cells to be detected with the present techniques. The data do not, however, prove monoclonality in tumour origin.
